ArticleFrontiers in oncology2026
Survival beyond treatment: patterns and determinants of disease-free survival in cervical cancer at a tertiary care center in India.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cervical cancer remains a major public health concern in India, with a substantial burden of late-stage diagnosis and limited survival data from tertiary care settings. Disease-free survival (DFS) is a key indicator of treatment effectiveness and recurrence risk, yet evidence on its determinants in Indian populations remains limited. This study aimed to assess DFS pattern and identify prognostic factors among cervical cancer patients treated at a tertiary care center in India. Data and methods: A retrospective-prospective cohort study was conducted at Sir Sunderlal Hospital, Banaras Hindu University, Varanasi. The study included 587 cervical cancer patients diagnosed between 2011 and 2021, with follow-up until February 2025. Disease-free survival was defined as the time from first follow-up after treatment completion to recurrence. Kaplan-Meier methods, log-rank tests, and Cox proportional hazards models with time-varying covariates were used to estimate survival and identify predictors. Results: The median follow-up duration was 23.4 months (IQR: 10.2-52.6). Most patients were aged ≤50 years (51.8%), from rural areas (68.5%), and presented with advanced disease (FIGO stage II: 36.3%; stage III: 45.8%). Squamous cell carcinoma accounted for 91.8% of cases, and 76.0% had tumor size ≥4 cm. Kaplan-Meier analysis showed a sharp decline in DFS during early follow-up, indicating a higher risk of recurrence in the initial years. Significant differences in DFS were observed by age (p=0.002), tumor size (p=0.005), vaginal involvement (p=0.011), lymph node involvement (p=0.012), and addiction status (p=0.023). In multivariable analysis, age ≤50 years (AHR = 1.64; 95% CI: 1.16-2.34), tumor size ≥4 cm (AHR = 2.98; 95% CI: 1.44-6.15), and vaginal involvement (AHR = 1.56; 95% CI: 1.06-2.29) were independently associated with poorer DFS. Tumor size also showed a significant time-varying effect (HR = 0.97, p=0.010). Conclusion: DFS in cervical cancer is strongly influenced by tumor burden and locoregional spread. The early decline in survival highlights the need for intensive follow-up during the first two years post-treatment. Targeted interventions focusing on early detection and risk-stratified management are essential to improve outcomes in resource-limited settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.